Specifically, the company has committed by 2030 to:
-Reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 33% versus 2017 levels to support efforts to limit the global temperature increase to well below 2°C, aligning with the 2015 Paris Climate Agreement.
-Improve transparency of Scope 3 GHG emissions and increase engagement on climate issues with key suppliers throughout the value chain.
-Increase energy efficiency by 10% and the total proportion of energy purchased or generated from renewable sources to 50%.
-Reduce total water withdrawal by 10% in areas projected to be in water stress.
-Assess and mitigate the environmental impact of pharmaceutical ingredients used in operations.
-Reduce the overall mass of secondary and tertiary packaging materials per unit dose and increase the proportion of recycled and responsibly-sourced materials by 10%.
-Assess the environmental lifecycle impact of key products.
-Continue to minimize waste generated from operations and the environmental impact of its disposal.
-Meet existing AMR Industry Alliance commitments to minimize antimicrobial discharges from the supply chain. 